4Pharma congratulates Professor Heikki Joensuu for receiving the 2012 Matti Äyräpää Award

Mika Leinonen (mika.leinonen a 4pharma.com), Jan 17th 2012

The Finnish Medical Society Duodecim awarded The Matti Äyräpää Prize to Academy Professor Heikki Joensuu. The Matti Äyräpää Prize is the most respected medical award in Finland.

Proferror Heikki Joensuu has excelled in cancer diagnostics and care for over 25 years. His research has mainly focused on breast and bowel cancer, and on the mechanisms of cancer origin. In recent years he has been involved in developing new types of targeted therapy with great impact in Finland and abroad.

4Pharma has had the privilege to collaborate with Professor Heikki Joensuu in several research projects, including high-profile phase III studies like the Finher, FinXX, SSG XVIII and SOLD studies. This collaboration has resulted in various publications co-authored by 4Pharma's statisticians - highlights are referenced below:

1. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H. Adjuvant Capecitabine, Docetaxel, Cyclophosphamide And Epirubicin for Early Breast Cancer: Final Analysis of a Randomized Trial (FinXX). J Clin Oncol. 2011 Nov 21. [Epub ahead of print]

2. Joensuu H, Sperinde J, Leinonen M, Huang W, Weidler J, Bono P, Kataja V, Kokko R, Turpeenniemi-Hujanen T, Jyrkkiö S, Isola J, Kellokumpu-Lehtinen PL, Paquet A, Lie Y, Bates M. Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol. 2011 Sep,22(9):2007-13.

3. Joensuu H, Sailas L, Alanko T, Sunela K, Huuhtanen R, Utriainen M, Kokko R, Bono P, Wigren T, Pyrhönen S, Turpeenniemi-Hujanen T, Asola R, Leinonen M, Hahka-Kemppinen M, Kellokumpu-Lehtinen PL. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: Final analysis of a randomised trial. Ann Oncol. 2010 May;21(5):968-73.

4. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Asola R, Kokko R, Ahlgren J, Auvinen P, Hemminki A, Paija O, Helle L, Nuortio L, Villman K, Nilsson G, Lahtela SL, Lehtiö K, Pajunen M, Poikonen P, Nyandoto P, Kataja V, Bono P, Leinonen M, Lindman H. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol. 2009 Dec;10(12):1145-51.

5. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial. J Clin Oncol. 2009 Dec 1;27(34):5671-3.

6. Bono P, Kellokumpu-Lehtinen PL, Alanko T, Kokko R, Asola R, Turpeenniemi-Hujanen T, Jyrkkiö S, Kataja V, Leinonen M, Joensuu H. Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial. Ann Oncol. 2009 Mar;20(3):595-6.

7. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20.

8. Joensuu H, Eriksson M, Hartmann J, Sundby Hall K, Schutte J, Reichardt A, Schlemmer M, Wardelmann E, Ramadori G, Al-Batran S, Nilsson BE, Monge O, Kallio R, Sarlomo-Rikala M, Bono P, Leinonen M, Hohenberger P, Alvegard T, Reichardt P. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSG XVIII/AIO). Poster presentation at the Plenary session of the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5 2011, Chicago, IL, USA (not yet available as a full manuscript).